Literature DB >> 30154633

Procedural Results and Immediate Outcomes following De Novo Saphenous Venous Graft Interventions.

Lalita Nemani1, Maddury Jyotsna1, Malleswara Rao D1.   

Abstract

Background  Distal embolization is the detrimental factor in SVG intervention. There is no specific treatment for it except prevention. Guidelines have endorsed the use of embolic protection devices; however, their use is not without complications, and increases the procedural time and cost for the patient. The objective of this study is to analyze the procedural results and immediate outcome in de novo SVG stenting. Methods  A retrospective observational study of patients who have undergone SVG-percutaneous coronary intervention at our institute. Baseline clinical, demographic data, intervention details, and in-hospital events are analyzed. Statistical analysis was done using Mini tab version 17. Chi-square testing, odds ratio, and 95% confidence intervals were calculated. Results  The study population included 96 lesions in 80 patients. Average age of the graft was 8.2 ± 4 years. Embolic protection devices were used only in 10%. Angiographic and clinical success was seen in 92.5%. Distal embolization was seen in 7.5%. Drug-eluting stent and shorter stents were associated with lesser distal embolization. Stent length (> 20 mm) proved to be an independent predictor of distal embolization. There was no correlation between distal embolization and age of patient, sex, hypertension, diabetes, and smoking, left ventricular function, age of graft, direct stenting, use of embolic device, and glycoprotein 2b/3a inhibitors. Conclusion  De novo SVG lesions can be stented with a high rate of angiographic and procedural success. Stent length is the only independent predictor of distal embolization. SVG interventions can be safely done in the absence of embolic protection devices irrespective of the graft age.

Entities:  

Keywords:  distal embolization; embolic protection device; no reflow; periprocedural MI; saphenous venous graft; slow flow; vein degeneration

Year:  2018        PMID: 30154633      PMCID: PMC6103757          DOI: 10.1055/s-0038-1636937

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  34 in total

1.  Are we making progress with percutaneous saphenous vein graft treatment? A comparison of 1990 to 1994 and 1995 to 1998 results.

Authors:  M K Hong; R Mehran; G Dangas; G S Mintz; A Lansky; K M Kent; A D Pichard; L F Satler; G W Stone; M B Leon
Journal:  J Am Coll Cardiol       Date:  2001-07       Impact factor: 24.094

2.  Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.

Authors:  Marco Roffi; Debabrata Mukherjee; Derek P Chew; Deepak L Bhatt; Leslie Cho; Mark A Robbins; Khaled M Ziada; Danielle M Brennan; Stephen G Ellis; Eric J Topol
Journal:  Circulation       Date:  2002-12-10       Impact factor: 29.690

Review 3.  Embolic protection of saphenous vein graft percutaneous interventions.

Authors:  Luther I Carter; Jaafer A Golzar; Jeffrey J Cavendish; Simon R Dixon
Journal:  J Interv Cardiol       Date:  2007-10       Impact factor: 2.279

4.  Correlates of adverse events during saphenous vein graft intervention with distal embolic protection: a PRIDE substudy.

Authors:  Ajay J Kirtane; Eugene R Heyman; Christopher Metzger; Jeffrey A Breall; Joseph P Carrozza
Journal:  JACC Cardiovasc Interv       Date:  2008-04       Impact factor: 11.195

5.  Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon.

Authors:  S Sdringola; A Assali; M Ghani; A Yepes; O Rosales; G W Schroth; K Fujise; H V Anderson; R W Smalling
Journal:  Catheter Cardiovasc Interv       Date:  2000-12       Impact factor: 2.692

6.  Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention.

Authors:  Luis Gruberg; Neil J Weissman; Augusto D Pichard; Ron Waksman; Kenneth M Kent; Lowell F Satler; William O Suddath; Ellen E Pinnow; Natalie Gevorkian; Joseph Lindsay
Journal:  Am Heart J       Date:  2003-03       Impact factor: 4.749

7.  Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators.

Authors:  M P Savage; J S Douglas; D L Fischman; C J Pepine; S B King; J A Werner; S R Bailey; P A Overlie; S H Fenton; J A Brinker; M B Leon; S Goldberg
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

8.  Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients.

Authors:  Alanna Coolong; Donald S Baim; Richard E Kuntz; A James O'Malley; Sachin Marulkar; Donald E Cutlip; Jeffrey J Popma; Laura Mauri
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

9.  Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft.

Authors:  Laurent Leborgne; Edouard Cheneau; Augusto Pichard; Andrew Ajani; Rajbabu Pakala; Hamid Yazdi; Lowell Satler; Kenneth Kent; William O Suddath; Ellen Pinnow; Daniel Canos; Ron Waksman
Journal:  Am Heart J       Date:  2003-09       Impact factor: 4.749

Review 10.  Insights into the pathogenesis of vein graft disease: lessons from intravascular ultrasound.

Authors:  Gavin J Murphy; Gianni D Angelini
Journal:  Cardiovasc Ultrasound       Date:  2004-07-21       Impact factor: 2.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.